Skip to main content
Caplight Logo









Aukera Therapeutics

Aukera Therapeutics

Private
BaselHealthcare & Life Scienceshttps://aukera-tx.com

Last Round

Seed

Dec 11, 2025

Total Funding Raised

$6.39M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Aukera Therapeutics is a biotechnology company developing therapies for mTOR-related disorders such as tuberous sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

selective RAPTOR inhibitorsmTORC1 signaling pathwayTuberous Sclerosis ComplexTSCAI drug discoverytechbiosmall molecule drugrare neurological disordersprecision medicinemTOR inhibitorsdrug discovery platformhard-to-drug targetsneurodegeneration

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aukera Therapeutics Comparables

Compare Aukera Therapeutics with similar companies based on industry and business-model similarity.

Aukera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aeovian Pharmaceuticals
84%
Cambrian Bio
78%
Johnson & Johnson
74%

Aukera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 11, 2025
GrantOct 19, 2022
AcceleratorFeb 21, 2022

Aukera Therapeutics Investors

Notable investors and investment history

Aukera Therapeutics investors
InvestorRounds
KickfundSeed
BaseLaunchAccelerator
Venture KickGrant
Zurcher KantonalbankSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 11, 2025

    $6M raised from Zurcher Kantonalbank and Kickfund.

  • Feb 21, 2022

    $540K raised from BaseLaunch

Aukera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aukera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aukera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range7
Year Founded2021
Last FundingDec 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?